Targeting newly identified ERβ/TGF‐β1/SMAD3 signals with the FDA‐approved anti‐estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma

Renal cell carcinoma (RCC) has the third highest mortality rate among urological tumors, and 20–30% of RCC patients present with metastatic RCC at the time of diagnosis. Although recent studies have indicated that estrogen receptor β (ERβ) could play promoting roles in RCC progression, the detailed...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Wenbin, He, Dalin, Chen, Yule, Yeh, Chiuan‐Ren, Hsu, Iawen, Huang, Qingbo, Zhang, Xu, Chang, Luke Sien‐Shih, Zuo, Li, Chen, Jiasheng, Doersch, Karen M., Chang, Chawnshang, Li, Lei, Yeh, Shuyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275262/
https://www.ncbi.nlm.nih.gov/pubmed/30171816
http://dx.doi.org/10.1002/1878-0261.12377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275262/
https://www.ncbi.nlm.nih.gov/pubmed/30171816
http://dx.doi.org/10.1002/1878-0261.12377

Ejemplares similares